13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674546
Total reported value
$4.8B
$4.8B
176 檔
36.1%
The Q4 2025 SEC filing reveals that Bellevue Group AG held a total portfolio value of $4.8B, covering 176 public equity positions.
Bellevue Group AG executed strategic sector rebalancing during Q4 2025, establishing 37 new positions while fully exiting 9 holdings and trimming 83 positions.
In terms of portfolio concentration, the top 5 core holdings (including RVMD, ARGX, IONS) accounted for 36.1% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 7.56% | +0.56% | -10.19% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.36% | +0.44% | -15.46% | |
| 3 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 7.20% | -1.63% | -23.10% | |
| 4 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 5.85% | -1.20% | +34.66% | |
| 5 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.58% | +0.08% | -3.39% | |
| 6 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.60% | — | +22.21% | |
| 7 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.46% | -1.01% | -7.63% | |
| 8 | SRRK | Scholar Rock Holding CORP | Stock-Other | 3.39% | -1.36% | +25.03% | |
| 9 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.36% | -1.84% | -0.14% | |
| 10 | ABT | Abbott Laboratories | Stock-Healthcare | 3.13% | -1.00% | -10.93% | |
| 11 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.90% | — | — | |
| 12 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.82% | -1.39% | -6.04% | |
| 13 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.57% | -0.53% | — | |
| 14 | SYK | Stryker CORP | Stock-Healthcare | 2.40% | +0.08% | -20.07% | |
| 15 | NUVL | Nuvalent Inc-a | Stock-Other | 1.98% | +0.17% | — | |
| 16 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 1.92% | -2.35% | +31174.62% | |
| 17 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.86% | +0.03% | +1.69% | |
| 18 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.84% | -0.15% | — | |
| 19 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.69% | -0.19% | +16.33% | |
| 20 | VERA | Vera Therapeutics Inc | Stock-Other | 1.63% | -0.10% | — | |
| 21 | MDT | Medtronic plc | Stock-Healthcare | 1.40% | -0.33% | +0.89% | |
| 22 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.34% | +0.59% | -0.00% | |
| 23 | IDXX | Idexx Laboratories Inc | Stock-Healthcare | 1.21% | -0.51% | +23.44% | |
| 24 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.10% | +0.35% | +3.01% | |
| 25 | DXCM | Dexcom Inc | Stock-Healthcare | 1.07% | -0.01% | +7.80% | |
| 26 | PODD | Insulet CORP | Stock-Healthcare | 1.01% | -0.41% | -11.94% | |
| 27 | BDX | Becton Dickinson And Co | Stock-Healthcare | 0.98% | -0.11% | -10.52% | |
| 28 | JBIO | Jade Biosciences Inc | Stock-Other | 0.98% | +0.26% | — | |
| 29 | DHR | Danaher CORP | Stock-Healthcare | 0.84% | -0.33% | +18.77% | |
| 30 | PEN | Penumbra Inc | Stock-Healthcare | 0.80% | -0.10% | EXIT | |
| 31 | RMD | Resmed Inc | Stock-Healthcare | 0.74% | -0.24% | -2.20% | |
| 32 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.72% | -1.15% | EXIT | |
| 33 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.71% | +0.09% | -38.71% | |
| 34 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 35 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.69% | +0.01% | -16.07% | |
| 36 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.66% | -0.37% | -8.32% | |
| 37 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.66% | -0.73% | — | |
| 38 | ABBV | Abbvie Inc | Stock-Healthcare | 0.58% | -0.27% | -21.08% | |
| 39 | CI | THE Cigna Group | Stock-Healthcare | 0.57% | -0.23% | -10.18% | |
| 40 | GKOS | Glaukos CORP | Stock-Healthcare | 0.56% | +0.01% | +368.36% | |
| 41 | JNJ | Johnson & Johnson | Stock-Healthcare | 0.50% | -0.14% | +69.50% | |
| 42 | ANNX | Annexon Inc | Stock-Other | 0.49% | -0.19% | — | |
| 43 | STE | STERIS plc | Stock-Healthcare | 0.49% | -0.09% | -13.89% | |
| 44 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.48% | — | EXIT | |
| 45 | ELV | Elevance Health Inc | Stock-Healthcare | 0.46% | +0.09% | -33.65% | |
| 46 | COO | Cooper Cos Inc/the | Stock-Healthcare | 0.45% | -0.16% | -0.10% | |
| 47 | GMED | Globus Medical Inc - A | Stock-Healthcare | 0.43% | -0.27% | -19.64% | |
| 48 | ALGN | Align Technology Inc | Stock-Healthcare | 0.42% | -0.07% | -2.21% | |
| 49 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 0.41% | -0.10% | -2.66% | |
| 50 | MCK | Mckesson CORP | Stock-Healthcare | 0.39% | -0.31% | -33.88% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | +2.2% | -10.19% | Trim |
| 2 | KRYS | Krystal Biotech Inc | +1.9% | +31174.62% | Add |
| 3 | VRTX | Vertex Pharmaceuticals Inc | +1.7% | +34.66% | Add |
| 4 | RNAGBP | Avidity Biosciences Inc | +1.7% | +22.21% | Add |
| 5 | SRRK | Scholar Rock Holding CORP | +0.9% | +25.03% | Add |
| 6 | GKOS | Glaukos CORP | +0.5% | +368.36% | Add |
| 7 | RLAY | Relay Therapeutics Inc | +0.4% | -0.00% | Trim |
| 8 | EW | Edwards Lifesciences CORP | +0.2% | +16.33% | Add |
| 9 | ISRG | Intuitive Surgical Inc | +0.2% | -7.63% | Trim |
| 10 | JNJ | Johnson & Johnson | +0.2% | +69.50% | Add |
| 11 | IDXX | Idexx Laboratories Inc | +0.2% | +23.44% | Add |
| 12 | DHR | Danaher CORP | +0.2% | +18.77% | Add |
| 13 | ANNX | Annexon Inc | +0.2% | — | Unchanged |
| 14 | MRK | Merck & Co. Inc. | +0.1% | +165.17% | Add |
| 15 | INSP | Inspire Medical Systems Inc | +0.1% | +71.81% | Add |
| 16 | CVS | Cvs Health CORP | +0.1% | +113.01% | Add |
| 17 | LLY | Eli Lilly & Co | +0.1% | -16.07% | Trim |
| 18 | WAY | Waystar Holding CORP | +0.1% | +86.07% | Add |
| 19 | GMED | Globus Medical Inc - A | 0% | -19.64% | Trim |
| 20 | ALGN | Align Technology Inc | 0% | -2.21% | Trim |
| 21 | ADPT | Adaptive Biotechnologies | 0% | +76.93% | Add |
| 22 | PEN | Penumbra Inc | 0% | -7.83% | Trim |
| 23 | COO | Cooper Cos Inc/the | 0% | -0.10% | Trim |
| 24 | AVTR | Avantor Inc | 0% | +167.28% | Add |
| 25 | BMY | Bristol-myers Squibb Co | 0% | +40.89% | Add |
| 26 | REGN | Regeneron Pharmaceuticals | 0% | -7.50% | Trim |
| 27 | AMGN | Amgen Inc | 0% | +23.36% | Add |
| 28 | TXG | 10x Genomics Inc-class A | 0% | +2.62% | Add |
| 29 | PFE | Pfizer Inc | 0% | +380.65% | Add |
| 30 | UTHR | United Therapeutics CORP | 0% | +47.54% | Add |
| 31 | TEVA | Teva Pharmaceutical-sp Adr | 0% | -22.68% | Trim |
| 32 | GPCR | Structure Therapeutics Inc | 0% | -54.04% | Trim |
| 33 | BBNX | Beta Bionics Inc | 0% | +12.45% | Add |
| 34 | BKD | Brookdale Senior Living Inc | 0% | +59.98% | Add |
| 35 | NAMS | NewAmsterdam Pharma Company N.V. | 0% | +148.69% | Add |
| 36 | BNTX | Biontech Se-adr | 0% | +28.86% | Add |
| 37 | BBIO | Bridgebio Pharma Inc | 0% | +18.45% | Add |
| 38 | ILMN | Illumina Inc | 0% | -3.60% | Trim |
| 39 | NVDA | Nvidia CORP | 0% | +460.26% | Add |
| 40 | MDGL | Madrigal Pharmaceuticals Inc | 0% | +20.52% | Add |
| 41 | MSFT | Microsoft CORP | 0% | +531.53% | Add |
| 42 | AAPL | Apple Inc | 0% | +106.34% | Add |
| 43 | CYTK | Cytokinetics Inc | 0% | +339.29% | Add |
| 44 | AMZN | Amazon.com Inc | 0% | +95.42% | Add |
| 45 | VKTX | Viking Therapeutics Inc | 0% | -9.75% | Trim |
| 46 | PTCT | Ptc Therapeutics Inc | 0% | +167.31% | Add |
| 47 | CORT | Corcept Therapeutics Inc | 0% | +755.34% | Add |
| 48 | GH | Guardant Health Inc | 0% | +53.81% | Add |
| 49 | CNC | Centene CORP | — | -2.93% | Trim |
| 50 | GILD | Gilead Sciences Inc | — | +5.73% | Add |
According to official SEC Form 13F filings, Bellevue Group AG reported a total U.S. public equity portfolio value of $4.8B across 176 disclosed positions in Q4 2025.
During Q4 2025, Bellevue Group AG's top holdings by market value included RVMD (7.6%)、ARGX (7.4%)、IONS (7.2%). The largest single position, RVMD, represented 7.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
AM6
市值: $152.9M
Top Position Liquidated / Trimmed
AGIO
前期市值: $149.1M
In Q4 2025, Bellevue Group AG made 176 total portfolio adjustments, initiating 37 new buys, adding to 47 positions, trimming 83 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.